Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;17(3):510-3.
doi: 10.3201/eid1703.101363.

Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa

N Sarita Shah  1 , Jessica Richardson, Prashini Moodley, Salona Moodley, Palav Babaria, Melissa Ramtahal, Scott K Heysell, Xuan Li, Anthony P Moll, Gerald Friedland, A Willem Sturm, Neel R Gandhi
Affiliations

Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa

N Sarita Shah et al. Emerg Infect Dis. 2011 Mar.

Abstract

We expanded second-line tuberculosis (TB) drug susceptibility testing for extensively drug-resistant Mycobacterium tuberculosis isolates from South Africa. Of 19 patients with extensively drug-resistant TB identified during February 2008-April 2009, 13 (68%) had isolates resistant to all 8 drugs tested. This resistance leaves no effective treatment with available drugs in South Africa.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Drug resistance among extensively drug-resistant tuberculosis isolates from Tugela Ferry, South Africa, 2005–2009: 4-drug resistance = isoniazid (INH), rifampin (RIF), ofloxacin (OFL), and kanamycin (KM); 5-drug resistance = INH, RIF, OFL, KM, and ethambutol (EMB) or streptomycin (SM); 6-drug resistance = INH, RIF, OFL, KM, EMB, and SM. Column for 2008–2009 indicates study population.
Figure 2
Figure 2
Determination of prevalence of tuberculosis (TB) and drug resistance among persons with suspected TB, Tugela Ferry, South Afica, 2008–2009. DST, drug susceptibility testing; MDR TB, multidrug-resistant TB; XDR TB, extensively drug-resistant TB.
See this image and copyright information in PMC

References

    1. Shah N, Wright A, Bai G, Barrera L, Boulahbal F, Martan-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13:380–7. 10.3201/eid1303.061400 - DOI - PMC - PubMed
    1. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010. global report on surveillance and response. Report no. WHO/HTM/TB/2010.3. Geneva: The Organization; 2010
    1. Sotgiu G, Ferrara G, Matteelli A, Richardson MD, Centis R, Ruesch-Gerdes S, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J. 2009;33:871–81. 10.1183/09031936.00168008 - DOI - PubMed
    1. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181:80–6. 10.1164/rccm.200907-0989OC - DOI - PubMed
    1. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575–80. 10.1016/S0140-6736(06)69573-1 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources